Evidence map›Paper›PMID 30397360›Full record

ArticleScientific reports2018

Genetic variation determines VEGF-A plasma levels in cancer patients.

Federico Innocenti, Chen Jiang, Alexander B Sibley, Amy S Etheridge, Ace J Hatch, Stefanie Denning, Donna Niedzwiecki, Ivo D Shterev, Jiaxing Lin, Yoichi Furukawa and 10 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 2 countries.

Federico InnocentiUNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA. innocent@email.unc.edu.
Chen JiangDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Alexander B SibleyDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.ORCID http://orcid.org/0000-0003-4552-1865
Amy S EtheridgeUNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
Ace J HatchDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Stefanie DenningUNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA.
Donna NiedzwieckiDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Ivo D ShterevDuke Human Vaccine Institute, Durham, North Carolina, USA.
Jiaxing LinDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
Yoichi FurukawaCenter for Genomic Medicine, RIKEN, Yokohama, Kanagawa Prefecture, Japan.
Michiaki KuboRIKEN Center for Integrative Medical Sciences, Yokohama, Kanagawa, Japan.
Hedy L KindlerUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA.
J Todd AumanDepartment of Pathology and Laboratory Medicine, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID http://orcid.org/0000-0002-9328-8829
Alan P VenookUniversity of California at San Francisco, San Francisco, California, USA.
Herbert I HurwitzDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Howard L McLeodMoffitt Cancer Center, Tampa, Florida, USA.
Mark J RatainUniversity of Chicago Comprehensive Cancer Center, Chicago, Illinois, USA.
Raluca GordanDepartment of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, North Carolina, USA.
Andrew B NixonDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Kouros OwzarDuke Cancer Institute, Duke University Medical Center, Durham, North Carolina, USA.
Duke Medical Center · USUniversity of North Carolina at Chapel Hill · USDuke University · USRIKEN Center for Integrative Medical Sciences · JPUniversity of Chicago · USMoffitt Cancer Center · USUniversity of California, San Francisco · US

Funding

Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$177.3M
CANCER AND LEUKEMIA GROUP B MINORITY SATELLITE SUPPLEMENU10CA031946 · NCI · UNIVERSITY OF CHICAGO · PI BERTAGNOLLI, MONICA M · 1985 to 2013
$158.4M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
CANCER &LEUKEMIA GROUP B STATISTICAL CENTERU10CA033601 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI SARGENT, DANIEL J. · 1985 to 2013
$69.4M
Statistical Methods for Cancer Clinical TrialsP01CA142538 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TSIATIS, ANASTASIOS A · 2010 to 2019
$21.3M
CANCER AND LEUKEMIA GROUP B GRANT REVISED APPLICATIONU10CA041287 · NCI · UNIVERSITY OF CHICAGO · PI KINDLER, HEDY L · 1986 to 2013
$3.9M
NCI National Clinical Trials Network-Network Lead Academic Participating SitesU10CA180836 · NCI · UNIVERSITY OF CHICAGO · PI CHMURA, STEVEN J, KINDLER, HEDY L · 2014 to 2018
$3.2M
NCTN Lead Academic Participating Sites ApplicationU10CA180838 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAREY, LISA A · 2014 to 2018
$2.8M
CANCER AND LEUKEMIA GROUP BU10CA047577 · NCI · DUKE UNIVERSITY · PI CRAWFORD, JEFFREY · 1988 to 2013
$2.2M
NCI National Clinical Trials Network U10U10CA180857 · NCI · DUKE UNIVERSITY · PI BARBORIAK, DANIEL P, BRIZEL, DAVID M · 2014 to 2018
$2.0M
Genome-Wide molecular epidemiology of treatment outcome and cancer riskK07CA140390 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI INNOCENTI, FEDERICO · 2009 to 2013
$648k
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
NCI NIH HHS K07 CA140390NCI NIH HHS P01 CA142538NCI NIH HHS U10 CA031946NCI NIH HHS U10 CA033601NCI NIH HHS U10 CA041287NCI NIH HHS U10 CA047577NCI NIH HHS U10 CA138561NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180836NCI NIH HHS U10 CA180838NCI NIH HHS U10 CA180857NCI NIH HHS U10 CA180882NIH HHS S10 OD018164
6 · The paper itself

Abstract

Angiogenesis is essential in tumor biology and is regulated by vascular endothelial growth factor (VEGF) ligands and receptors. Here we aimed to discover genetic variants associated with levels of circulating angiogenic proteins in cancer patients. Plasma was collected at baseline in 216 pancreatic and 114 colorectal cancer patients. Thirty-one angiogenic proteins were measured by ELISA. 484,523 Single Nucleotide Polymorphisms (SNP) were tested for association with plasma levels for each protein in pancreatic cancer patients. Three top-ranked hits were then genotyped in colorectal cancer patients, where associations with the same proteins were measured. The results demonstrated rs2284284 and MCP1 (P-value = 6.7e-08), rs7504372 and VEGF-C (P-value = 9.8e-09), and rs7767396 and VEGF-A (P-value = 5.8e-09) were SNP-protein pairs identified in pancreatic cancer patients. In colorectal cancer patients, only rs7767396 (A > G) and VEGF-A was validated (P-value = 5.18e-05). The AA genotype of rs7767396 exhibited 2.04-2.3 and 2.7-3.4-fold higher VEGF-A levels than those with AG and GG genotypes. The G allele of rs7767396 reduces binding of the NF-AT1 transcription factor. In conclusion, a common genetic variant predicts the plasma levels of VEGF-A in cancer patients through altered binding of NF-AT1.

Indexed as

Polymorphism, Single NucleotideAdultAgedAged, 80 and overColorectal NeoplasmsFemaleHumansMaleMiddle AgedNeovascularization, PathologicNFATC Transcription FactorsRNA, MessengerVascular Endothelial Growth Factor AYoung AdultNFATC Transcription FactorsRNA, MessengerVascular Endothelial Growth Factor A

Identifiers

PMID30397360
PMCPMC6218528
OpenAlexW2898871632

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.